36 results
Page 2 of 2
6-K
EX-99.1
bjj8i83 0uo9
19 Nov 21
Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis
4:01pm
6-K
EX-99.1
rye690zewagy x01x
19 Nov 21
Primary endpoint met with all three CBP-201 arms achieving significant improvements
8:00am
6-K
ssph0oh
8 Sep 21
Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating
8:31am
6-K
EX-99.1
8jvpi
8 Sep 21
Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating
8:31am
6-K
EX-99.1
e52v48i7mycaim4
2 Sep 21
Connect Biopharma Announces First Patient Dosed in China Pivotal Trial
4:40pm
6-K
EX-99.2
z6t ojt5la
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
6-K
EX-99.3
xp5ewkg
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
6-K
EX-99.1
stbhqcac4p18gy5
3 Jun 21
Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus
6:04am
6-K
EX-99.2
011kdik7j 8dua6ie
3 Jun 21
Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus
6:04am
6-K
EX-99.1
ghrnvrnucxrvqfrlar
17 May 21
Connect Biopharma Announces First
5:27pm
424B4
48rf17290l9v0b2
19 Mar 21
Prospectus supplement with pricing info
4:49pm
F-1/A
ryzqt0
18 Mar 21
Registration statement (foreign) (amended)
6:15am
F-1/A
bxliqrx13j9rv27 al
12 Mar 21
Registration statement (foreign) (amended)
5:02pm
F-1
fpo3lz5qz8x2cw86cr
26 Feb 21
Registration statement (foreign)
4:56pm
DRS/A
1d46y 3pbq0tb1297vz
26 Jan 21
Draft registration statement (amended)
12:00am
DRS
jxclmuv
17 Dec 20
Draft registration statement
12:00am